Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
28.8M
-
Shares change
-
+50.3K
-
Total reported value, excl. options
-
$225M
-
Value change
-
-$943K
-
Put/Call ratio
-
0.16
-
Number of buys
-
50
-
Number of sells
-
-40
-
Price
-
$7.83
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q4 2024
125 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q4 2024.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.8M shares
of 45.1M outstanding shares and own 63.85% of the company stock.
Largest 10 shareholders include Paradigm Biocapital Advisors LP (4.24M shares), BlackRock, Inc. (3M shares), ACORN CAPITAL ADVISORS, LLC (2.86M shares), Sofinnova Investments, Inc. (2.19M shares), VANGUARD GROUP INC (2M shares), Polar Capital Holdings Plc (1.83M shares), Caligan Partners LP (1.77M shares), STATE STREET CORP (1.31M shares), Logos Global Management LP (1M shares), and GEODE CAPITAL MANAGEMENT, LLC (822K shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.